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ABSTRACT 
New phthalimido derivatives incorporated with chalcone, pyrazole,  pyrazoline, and pyrimidine moieties were synthesized 
and evaluated for their antimicrobial activities against bacterial and fungal strains. 2-{4-[1-Acetyl-5-(4-chlorophenyl)-4,5-
dihydro-1H-pyrazol-3-yl]phenyl} isoindoline-1,3-dione (7) showed broad spectrum antibacterial activity against both G+ 
and G- bacteria. While, (E)-2-{4-[3-(4-chlorophenyl)acryloyl]phenyl}isoindoline-1,3-dione (4b) showed promising antifungal 
activity.  
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INTRODUCTION 
     Despite of increasing synthesis of antimicrobial agents, a big problem is still present. Resistance to antimicrobial 
agents is considered as the real challenge in the course of treatment of infectious diseases. Structural modification of 
already known antimicrobial drugs by introducing different nuclei and moieties results in a strategy for the development of 
novel drugs. 
     Phthalimides are bicyclic non-aromatic nitrogen heterocycles. They are considered as starting materials and 
intermediates for the synthesis of different alkaloids [1] .Phthalimides have been received a great deal of attention due to 
their biological activities such as antibacterial
 
[2-4]
 
1, antifungal [3], anti-inflammatory [5-7], antitumor [8-11], anti HIV-1 
[12,13] and anxiolytic activities [14], Figure 1. 
      Moreover, chalcones are also known to have a diverse array of biological activities among with antiallergic [15], anti-
inflammatory [16,17], anticancer [18], antimalarial[19] and antimicrobial activities [20,21]. 
     Also, chalcones are considered as useful synthons in the synthesis of many bioactive molecules such as: pyrazolines 
and pyrimidines. 
     Both pyrazolines [2] 1, pyrazoles [22] 2 and pyrimidines [2] 1 have been proved to posses antibacterial [22,23] , 
antifungal [22,23] and  antimicrobial
 
[24, 25] activities, Figure 1. 
 
 
 
   
 
    Prompted by all the above facts, we thought it is worthwhile to synthesize new compounds containing phthalimide 
scaffold attached to chalcone function as well as different heterocyclic rings like pyrazole, pyrazoline and pyrimidine which 
have been found to have an interesting profile of antimicrobial activity. The design of the new  compounds is illustrated in 
Figure 2. 
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Fig.1: Previously synthesized antimicrobial agents with the required pharmacophores. 
Fig. 2: General design for the newly synthesized compounds 3-8a&b. 
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MATERIALS AND METHODS 
Chemistry 
      Melting points were determined using a Griffin apparatus and were uncorrected. IR spectra were recorded on 
Shimadzu IR 435 spectrophotometer and values were represented in cm
-1
, Cairo University, Cairo, Egypt,  
1
H NMR and 
13
C NMR were carried out on Bruker 400 MHz spectrophotometer, Beni Suef University, Beni Suef, Egypt, using TMS as 
an internal standard and chemical shifts were recorded in ppm on 
δ scale. The electron impact (EI) mass spectra were recorded on Hewlett Packard 5988 spectrometer, Microanalytical 
center, Cairo University, Cairo, Egypt. Thin-layer chromatography (TLC) was performed on Merk TLC aluminium sheets 
silica gel 60 F254 with detection by UV quenching at 254nm to follow the course of reactions and to check the purity of 
products. All reagents and solvents were purified and dried by standard techniques. 
General procedure for preparation of 2-(4-acetylphenyl)isoindoline-1,3-dione (3) 
A mixture of phthalic anhydride (1) (1.48g, 0.01mol) and p-aminoacetophenone (2) (1.35g, 0.01mol) in glacial acetic acid 
(30 mL) was heated under reflux for 10hrs. The solid separated on hot was filtered, dried and crystallized from propanol as 
colorless crystals, m.p. 244-246 
o
C, yield 70%. Analysis: for C16H11NO3, M.Wt. 265.26, calculated: C, 72.45; H, 4.18; N, 
5.28. Found: C, 72.31; H, 4.10; N, 5.26. IR (KBr, cm
-1
): 1782, 1714, 1677 (3C=O). 
1
H NMR (DMSO-d6, δ ppm): 2.63 (s, 
3H, CH3), 7.64 (d, 2H, J= 8.4 Hz, Haromatic), 7.93 (m, 2H, Haromaic), 8.00 (m, 2H, Haromatic), 8.12 (d, 2H, J= 8.4 Hz, Haromatic). 
MS: (m/z) 266 [(M+1)
+.
, 5.87%], 265 [(M)
+.
, 26.65%], 76 [(C6H4)
+.
, 100%]. 
General procedure for preparation of compounds 4a-d 
A mixture of compound 3 (2.65g, 0.01 mol) and the appropriate aldehyde (0.01 mol) in 5% ethanolic potassium hydroxide 
(30 mL) was stirred at room temperature for 24hrs. The reaction mixture was poured onto ice cold water and neutralized 
with dilute hydrochloric acid. The separated solid was filtered off, dried and crystallized from acetone to give compounds 
4a-d.    
(E)-2-{4-[3-(4-Hydroxyphenyl)acryloyl]phenyl}isoindoline-1,3-dione (4a) 
As brown crystals, m.p. 214-216
o
C, yield 59%. Analysis: for C23H15NO4, M.Wt. 369.37, calculated: C, 74.79; H, 4.09; N, 
3.79. Found: C, 74.66; H, 3.95; N, 3.51. IR (KBr, cm
-1
): 3247 (OH), 1713, 1670, 1652 (3C=O). 
1
H NMR (DMSO-d6, δ ppm): 
7.53 (d, 2H, J= 6 Hz, Haromatic), 7.57 (m, 4H, Haromatic), 7.61 (m, 4H, Haromatic), 7.67 (d, 1H,  J= 14 Hz, =CH), 7.89 (d, 1H, J= 
10.4 Hz, =CH), 7.93 (d, 2H, J= 7.6 Hz, Haromatic), 10.71 (s, 1H, OH, exchangeable with D2O).  MS: (m/z) 370 [(M+1)
+.
, 
48.97%], 369 [(M)
+.
, 41.38%], 119 [(C7H5NO)
+.
, 100%]. 
(E)-2-{4-[3-(4-Chlorophenyl)acryloyl]phenyl}isoindoline-1,3-dione (4b) 
As yellow crystals, m.p. 220-222 
o
C, yield 65%. Analysis: for C23H14ClNO3, M.Wt. 387.82, calculated: C, 71.23; H, 3.64; N, 
3.61. Found: C, 71.52; H, 3.34; N, 3.59. IR (KBr, cm
-1
): 1779, 1713, 1655 (3C=O). 
1
H NMR (DMSO-d6, δ ppm): 7.26 (m, 
4H, Haromatic), 7.46 (d, 2H, J= 7.64 Hz, Haromatic), 7.63 (d, 1H, J= 14.8 Hz, =CH), 7.84 (d, 1H, J= 15.2 Hz, =CH), 7.91 (m, 4H, 
Haromatic), 7.97 (m, 2H, Haromatic). MS: (m/z) 389 [(M+1)
+.
, 7.42%], 388 [(M)
+.
, 5.79%], 80 [(C4O2)
+.
, 100%]. 
 (E)-2-{4-[3-(4-(Dimethylamino)phenyl)acryloyl]phenyl}isoindoline-1,3-dione (4c) 
As dark brown crystals, m.p. 153-155 
o
C, yield 49 %. Analysis: for C25H20N2O3, M.Wt. 396.15, calculated: C, 75.74; H, 
5.08; N, 7.07. Found: C, 75.63; H, 4.97; N, 6.87. IR (KBr, cm
-1
): 1714, 1670, 1652 (3C=O). 
1
H NMR (DMSO-d6, δ ppm): 
3.01 (s, 6H, 2CH3), 7.56 (m, 4H, , Haromatic), 7.67 (d, 1H, J= 14.8 Hz, =CH), 7.83 (d, 1H, J= 14 Hz, =CH), 8.12 (m, 8H, 
Haromatic).  MS: (m/z) 397 [(M+1)
+.
, 55.56%], 396 [(M)
+.
, 73.74%], 82 [(C4H2O2)
+.
, 100%]. 
(E)-2-{4-[3-(4-Nitrophenyl)acryloyl]phenyl}isoindoline-1,3-dione (4d) 
As dark yelow crystals, m.p. 195-197 
o
C, yield 62 %. Analysis: for C23H14N2O5, M.Wt. 398.37, calculated: C, 69.34; H, 
3.54; N, 7.03. Found: C, 69.61; H, 3.33; N, 6.95. IR (KBr, cm
-1
): 1713, 1669, 1653 (3C=O). 
1
H NMR (DMSO-d6, δ ppm): 
7.39 (d, 2H, J= 6 Hz, Haromatic), 7.73 (d, 1H, J= 14.8 Hz, =CH), 7.88 (d, 1H, J= 15.6 Hz, =CH), 7.92 (m, 5H, Haromatic), 8.20 
(m, 5H, Haromatic).  MS: (m/z) 399 [(M+1)
+.
, 0.86%], 398 [(M)
+.
, 56.03%], 80 [(C4O2)
+.
, 100%]. 
General procedure for preparation of 2-{4-[3-(4-chlorophenyl)-1H-pyrazol-5-yl]phenyl}isoindoline-1,3-dione (5) 
A mixture of the chalcone derivative 4b (3.87g, 0.01 mol) and hydrazine hydrate 99% (2.5g, 0.05 mol) in absolute ethanol 
(30 mL) was heated under reflux for 8hrs. The reaction mixture was poured onto ice cold water. The formed solid was 
filtered off, dried and crystallized from ethanol to give compound 5. As white crystals, m.p. 239-241 
o
C, yield 45 %. 
Analysis: for C23H14ClN3O2, M.Wt. 399.83, calculated: C, 69.09; H, 3.53; N, 10.51. Found: C, 69.22; H, 3.75; N, 10.55. IR 
(KBr, cm
-1
): 2334 (NH), 1713, 1655 (2C=O). 
1
H NMR (DMSO-d6, δ ppm): 7.51 (d, 2H, J= 8 Hz, Haromatic), 7.59 (m, 4H, 
Haromatic), 7.67 (m, 4H, Haromatic), 7.78 (s, 1H, Hpyrazole), 7.87 (d, 2H, J= 8.4 Hz, Haromatic), 10.51 (s, 1H, NH, exchangeable 
with D2O). 
13
C NMR (DMSO-d6, δ ppm): 100.79, 123.20, 126.25, 127.33, 129.39, 129.78, 130.41, 132.69, 132.70, 133.22, 
134.34, 138.99, 147.72, 149.45, 168.38. MS: (m/z) 401 [(M+1)
+.
, 22.39%],  104 [(C7H6N)
+
, 100%]. 
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General procedure for preparation of 5-(4-chlorophenyl)-3-[4-(1,3-dioxoisoindolin-2-yl)phenyl]-1H-pyrazole-1-
carbaldehyde (6) 
A mixture of the chalcone derivative 4b (3.87g, 0.01 mol) and hydrazine hydrate 99% (2.5g, 0.05 mol) in formic acid (30 
mL) was heated under reflux for 10hrs. The reaction mixture was poured onto ice cold water. The formed solid was filtered 
off, dried and crystallized from ethanol to give compound 6. As yellow crystals, m.p. 237-239
o
C, yield 49 %. Analysis: for 
C24H14ClN3O3, M.Wt. 427.84, calculated: C, 67.38; H, 3.30; N, 9.82. Found: C, 67.52; H, 3.71; N, 9.73. IR (KBr, cm
-1
): 
1726, 1712, 1654 (3C=O). 
1
H NMR (DMSO-d6, δ ppm): 7.38 (d, 2H, J= 8.4 Hz, Haromatic), 7.76 (m, 2H, Haromatic), 7.94 (m, 
7H, Haromatic), 8.16 (m, 2H, Haromatic), 8.87 (s, 1H, CHO). 
13
C NMR (DMSO-d6, δ ppm): 103.21, 124.38, 126.66, 127.86, 
129.94, 130.25, 130.49, 130.63, 130.75, 132.03, 140.83, 145.50, 148.44, 167.31, 187.77.  MS: (m/z) 427 [(M)
+.
, 23.85%],  
69 [(C2HN2O)
+
, 100%]. 
  General procedure for preparation of 2-{4-[1-acetyl-5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3-
yl]phenyl}isoindoline-1,3-dione (7) 
A mixture of the chalcone derivative 4b (3.87g, 0.01 mol) and hydrazine hydrate 99% (2.5g, 0.05 mol) in glacial acetic acid 
(30 mL) was heated under reflux for 10hrs. The reaction mixture was poured onto ice cold water. The formed solid was 
filtered off, dried and crystallized from ethanol to give compound 7. As brown crystals, m.p. 278-280 
o
C, yield 52 %. 
Analysis: for C25H18ClN3O3, M.Wt. 443.88, calculated: C, 67.65; H, 4.09; N, 9.47. Found: C, 67.42; H, 3.81; N, 9.33. IR 
(KBr, cm
-1
): 1727, 1690, 1658 (3C=O). 
1
H NMR (DMSO-d6, δ ppm): 2.28 (2, 3H, CH3), 3.11 (dd, 1H, H
4
pyrazoline, J= 18.4, 4 
Hz), 3.81 (dd, 1H, H
4
pyrazoline, J= 11.6, 6 Hz), 5.51 (dd, 1H, H
5
pyrazoline, J= 10.8, 7.6 Hz), 7.19 (d, 2H, J= 8 Hz, Haromatic), 7.36 
(d, 2H, J= 8 Hz, Haromatic), 7.66 (m, 4H, Haromatic), 7.71 (d, 2H, J= 8.8 Hz, Haromatic), 7.88 (d, 2H, J= 8 Hz, Haromatic).  MS: (m/z) 
444 [(M)
+.
, 11.42%],  313 [(C19H11N3O2)
+.
, 100%]. 
General procedure for preparation of compounds 8a&b 
A mixture of the chalcone derivative 4b (3.87g, 0.01 mol) and urea or thiourea (0.01 mol) in absolute ethanol (30 mL) 
containing sodium hydroxide (1g) was heated under reflux for 10hrs. The reaction mixture was poured onto ice cold water, 
neutralized with dilute hydrochloric acid. The formed solid was filtered off, dried and crystallized from ethanol to give 
compounds 8a&b. 
2-{4-[6-(4-chlorophenyl)-2-oxo-1,2-dihydropyrimidin-4-yl]phenyl}- isoindoline-1,3-dione (8a) 
As brown crystals, m.p. 258-260 
o
C, yield 45 %. Analysis: for C24H14ClN3O3, M.Wt. 427.07, calculated: C, 67.38; H, 3.30; 
N, 9.82. Found: C, 67.12; H, 3.52; N, 9.76. IR (KBr, cm
-1
): 3347 (NH), 1730, 1686 (2C=O). 
1
H NMR (DMSO-d6, δ ppm): 
7.58 (m, 4H, Haromatic), 7.67 (m, 4H, Haromatic), 7.89 (m, 4H, Haromatic), 8.21 (s, 1H, Hpyrimidine), 10.75 (s, 1H, NH, 
exchangeable with D2O).  MS: (m/z) 427 [(M)
+.
, 10.27%],  77 [(C6H5)
+.
, 100%]. 
2-{4-[6-(4-chlorophenyl)-2-thioxo-1,2-dihydropyrimidin-4-yl]phenyl}- isoindoline-1,3-dione (8b) 
As brown crystals, m.p. 232-234 
o
C, yield 49 %. Analysis: for C24H14ClN3O2S, M.Wt. 443.90, calculated: C, 64.94; H, 3.18; 
N, 9.47. Found: C, 65.10; H, 3.35; N, 9.52. IR (KBr, cm
-1
): 3348 (NH), 1731, 1685 (2C=O), 1229 (C=S). 
1
H NMR (DMSO-
d6, δ ppm): 7.62 (m, 4H, Haromatic), 7.82 (m, 4H, Haromatic), 7.92 (m, 4H, Haromatic), 8.00 (s, 1H, Hpyrimidine), 10.69 (s, 1H, NH, 
exchangeable with D2O).  MS: (m/z) 444 [(M)
+.
, 15.16%],  77 [(C6H5)
+.
, 100%]. 
Antimicrobial evaluation 
A. Determination of antimicrobial activities: 
      The MIC and MBCs of test compounds were determined against four reference bacterial strains: two gram positive 
bacteria, Staphylococcus aureus (ATCC 6538) and Bacillus subtilis (ATCC 6633), and two gram negative bacteria, 
Escherichia coli (ATCC 5087) and Pseudomonas aeruginosa (ATCC 9027). Candida albicans (ATCC 60193) and 
Aspergillus niger (ATCC 171809) were choose as standard strains of fungi. All assays were conducted in triplicates under 
strict aseptic conditions. 
B. Determination of the Minimum Inhibitory Concentrations (MICs): 
     The preliminary MICs were firstly determined by the microbroth dilution method as per Clinical Laboratory Standard 
Institute guidelines (CLSI, 2009) [26]. Briefly, 100 μL of double strength DMSO (Sigma-Aldrich, Germany) were placed in 
each well of 96-well microtiter plate. Aliquot of 100 μL of the solution to be tested were added to the first column. Then 2-
fold dilutions were carried out from one well to the next up to final well in each row for each tested compound. MICs were 
then determined using agar disc diffusion technique according to Kirby Bauer disc diffusion method with some 
modifications according to (CLSI 2009) [26]. A total of 15 mL of molten (45
o
C) Nutrient agar (sigma-Aldrich, Germany) 
were added into sterilized petri-dishes, allowed to solidify then 33.3μL of each bacteria and fungi suspension (10
5
 CFU 
mL
-1
) were surface inoculated. Finally, discs were wet with 10μL of each dilution of the tested solution then placed into 
each plate and were allowed to stand for 10 min and then all plates were transferred and incubated at 37
o
C for 24h for 
bacterial strains and 30
o
C for 48h fungal strains under aerobic conditions. The zones of inhibitions were then measured in 
mm. 
The results are summarized in Table 1. The zones of inhibition for most active compounds are represented in Figure 3. 
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RESULTS AND DISCUSSION 
Chemistry: 
      In the present work, starting from 2-(4-acetylphenyl)isoindoline-1,3-dione (3), different compounds of phthalimide 
derivatives were prepared. 
      Thus, the reaction of 3 with different aromatic  aldehydes, namely: 4-hydroxy, 4-chloro, 4-N,N-dimethylamino and 4-
nitrobenzaldehyde resulted in the formation of chalcone derivatives 4a-d. Merging pyrazole moiety with phthalimide core in 
5 and 6 was obtained from the reaction of compound 4b with hydrazine hydrate 99% in either absolute ethanol or 
 formic acid, respectively rather than pyrazoline derivatives A and B, sequentially (confirmed by IR, 
1
H NMR, 
13
C NMR and 
Mass spectroscopy). On the other hand, compound 7 was yielded from 4b and hydrazine hydrate 99% in glacial acetic 
acid. Finally, compound 4b reacted with both urea and thiourea to give 2-thio(oxo)- 1,2-dihydropyrimidine derivatives 
8a&b, respectively. (Scheme 1) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Biological activity  
Antimicrobial activity 
      All of the newly synthesized compounds were evaluated for their in vitro antibacterial activity against two gram 
positive bacterial strains (S. aureus and B. subtlis), and two strains of gram negative bacteria (E. coli and P. aeruginosa). 
They were also tested for their in vitro antifungal activity against two mycotic strains namely, C. albicans and A. niger. 
Determination of the preliminary antibacterial and antifungal activity were investigated using agar-diffusion method. The 
results were recorded for each tested compound as the average diameter of inhibition zones (IZ) of bacterial or fungal 
growth around the discs in mm, Table 1. 
 Based on the data obtained from Table 1, Pyrazoline derivative 7 was the most active among test compounds as 
antibacterial agent showing broad spectrum antibacterial activities against (G+) and (G–) strains. 
 While, the tested compounds (4a, 4b, 4d and 8a) showed narrow spectrum (G+) antibacterial activities for (S. aureus and 
B. subtils). 
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Scheme 1: Reagents and Conditions: a, gl. acetic acid, reflux 10hrs; b, ArCHO, KOH, absolute ethanol, stirring 
24hr; c, NH2NH2, absolute ethanol, reflux 8hrs; d, NH2NH2, formic acid, reflux 10hrs; e, NH2NH2, gl. acetic acid, 
reflux 10hrs; f, urea or thiourea, NaOH,  absolute ethanol, reflux 10hrs. 
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One of the tested compounds 4b exhibited antifungal activities against C. albicans and A. niger (IZ = 20, 12mm, 
respectively). 
The chalcone derivative 4b, pyrazoline containing compound 7 and pyrimidinone derivative 8a possessed activity against 
spore forming organisms (A. niger and/or B. subtilis). 
No antimicrobial activities were detected in the tested compounds { (4-N,N-dimethylamino chalcone derivative) 4c, 
(Pyrazole analogue) 5, (N-formyl pyrazole derivative) 6  and (thioxopyrimidinone analogue) 8b} for S. aureus, B. subtilis, 
E. coli, P. aeruginosa, C. albicans and A. niger during whole concentrations. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                 
         
Figure 3: Zone of inhibition at different concentrations (mm) by paper disc diffusion. 
 
Fungi Gram -ve Gram +ve 
Compd. no. 
A. niger C. albicans E. coli P.aeruginosa B. subtilis S. aureus 
0 0 0 0 0 11 4a 
12 20 0 0 0 12 4b 
0 0 0 0 0 0 4c 
0 0 0 0 0 11 4d 
0 0 0 0 0 0 5 
0 0 0 0 0 0 6 
0 0 15 10 11 10 7 
0 0 0 0 13 12 8a 
0 0 0 0 0 0 8b 
Table 1: Antimicrobial activity of the newly synthesized compounds against G+, G- and fungal strains 
 expressed as IZ (mm). 
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CONCLUSION 
     Antibacterial and antifungal activities for all the newly synthesized phthalimido derivatives were in vitro evaluated. The 
most active compound as antibacterial agent against both G+ and G- strains was 7. Chalcone derivative 4b possessed 
potent antimicrobial activity against fungi and G+ organisms. Moreover, the two other chalcone derivatives 4a and 4d 
shared their activities with 8a against G+ bacteria.Whereas, no antimicrobial activities were observed in compounds 4c, 5, 
6 and 8b. 
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